PV Bulletin

Deep Heat Extra Strength 100g Cream

Mentholatum Australasia Pty Ltd is conducting an urgent recall of two batches of Deep Heat Extra Strength 100g cream due to contamination.

Primary source: Safety monitoring and information

PV Impact Brief

Urgency: HighConfidence: high

What changed

An urgent recall of two batches of Deep Heat Extra Strength 100g cream has been initiated due to contamination.

Why it matters

The urgent recall presents a direct safety risk related to product contamination, necessitating immediate attention from regulatory and safety management teams.

Action needed

Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 7, 2026

Full briefing

Practical implication

Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.

An urgent recall has been initiated for two batches of Deep Heat Extra Strength 100g cream in Australia due to contamination concerns, posing a direct safety risk.

What changed: An urgent recall of two batches of Deep Heat Extra Strength 100g cream has been initiated due to contamination.

Why it matters: The urgent recall presents a direct safety risk related to product contamination, necessitating immediate attention from regulatory and safety management teams.

Practical implication: Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.

View original source

  • Source: TGA Safety Alerts - Market actions feed
  • Published at source: 2026-09-07T00:00:00.000Z
  • Discovered by monitor: 2026-09-07T21:35:40.094Z

Published from the regulator source ingestion pipeline after PV impact triage.

Related updates for your role

publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026

New EU supply chain to end Visudyne shortage

Urgency: High

Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.

Signal ManagementSignal Management Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Signal Management Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

Parenteral iron-containing medicinal products - referral

Urgency: High

Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

PRAC 3 September 2026: Starts safety review of injectable iron-containing medicines Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026 4 September 20

Urgency: High

Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 4, 2026

Dengue Tetravalent Vaccine (Live, Attenuated) Takeda - opinion on medicine for use outside EU

Urgency: High

Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward